Adiponectin, an adipokine with anti-inflammatory, antioxidant, and anti-fibrotic properties, is markedly reduced during the progression from NAFLD to NASH (83). This evidence concerns the gene ADIPOQ and metabolic dysfunction-associated steatohepatitis.